Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function

Abstract

Objective: To explore the effect of risperidone combined with olanzapine in the treatment of schizophrenia and its influence on cognitive function.
 Methods: Ninety-eight schizophrenic patients in our hospital who were admitted and treated between June 2018 and December 2019 were selected. The study group was treated with risperidone combined with olanzapine, and the control group was treated with risperidone. The clinical efficacy, Positive and Negative Syndrome Scale (PANSS) score, Wisconsin Card Sorting Test (WCST) result and adverse reactions of the two groups were compared.
 Results: After treatment, the scores of classification completion number and correct times of the observation group were higher than those of the control group, and the scores of the random error number and continuous error number were higher than those of the control group; the differences were statistically significant (P<0.05). The total effective rate of the observation group was 95.56%, which was higher than 77.78% of the control group (P<0.05). After treatment, the PANSS scores of the observation group were significantly lower than those of the control group (P<0.05). The total incidence of adverse reactions in the observation group and control group were 9.30% and 6.98%, respectively, and there was no significant difference between the two groups (P>0.05).
 Conclusion: Risperidone combined with olanzapine in the treatment of schizophrenia can effectively reduce symptoms of patients and induce fewer adverse reactions, showing high safety and significant treatment effect.
 doi: https://doi.org/10.12669/pjms.37.3.3348
 How to cite this:Yang L, Qi X. Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function. Pak J Med Sci. 2021;37(3):---------. doi: https://doi.org/10.12669/pjms.37.3.3348
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Clinical Analysis on the Effects of Tandospirone Citrate Assisted by Drawing Therapy on Medication Compliance and Sleep Quality in Patients with Anxiety Disorders

“…The control group was treated with tandospirone citrate (Sichuan Creed Pharmaceutical Co., Ltd., approved by H20052328, 5 mg ∗ 24 capsules), 10 mg orally each time, 3 times a day. Insomniacs are allowed to take zolpidem before going to bed (Sanofi (Hangzhou) Pharmaceutical Co., Ltd., approved by Chinese medicine H20044989), and the dose is controlled at 5–10 mg/d [ 7 ].…”

Study on the clinical correlation between the expression of serum TNF-α and iNOS as well as cognitive impairment and disease burden in patients with schizophrenia

“…Relevant studies have shown that patients with schizophrenia have a certain degree of cognitive dysfunction or impairment. 20,21 In this study, the scores of trail making test in the observation group were significantly higher than those of the control group, while the scores of symbolic coding, verbal memory, maze, visual memory, and semantic fluency were significantly lower than those of the control group, indicating that the patients had a certain degree of cognitive dysfunction in the early stage of onset. Pearson correlation analysis showed that the levels of serum TNF-α and iNOS in the observation group were positively correlated with the trail making test scores, and negatively correlated with the scores of symbolic coding, verbal memory, maze, visual memory, and semantic fluency.…”

Challenges and opportunities in the diagnosis and treatment of early-onset psychosis: a case series from the youth affective disorders clinic in Stockholm, Sweden

“…However, not all patients may respond similarly, and these treatments are not devoid of side effects. For instance, antipsychotics are linked with increased neurological and metabolic adverse effects in young patients 26 , 27 , though strategies exist to lessen these effects 20 , 27 . Hyperprolactinemia is a clinically significant adverse effect of risperidone treatment in both adults 28 , 29 and, putatively, adolescents 30 .…”

“…To further address these symptoms, Risperidone was initiated at 0.5 mg/day, with rapid increments of 0.5 mg every third day, targeting a dosage of 4 mg/day. Low-dose Olanzapine (5 mg) was also added, influenced by case studies suggesting that it can mitigate the common side effects of Risperidone and thereby enhance treatment tolerability 20 . During the titration phase for Risperidone, the patient experienced sedation and excessive daytime sleepiness, both of which fully resolved upon reaching the target dose.…”